Uncategorized

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – April 7, 2023

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on April 5, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 22,000 shares of its common stock to three new employees, consisting of stock options to purchase […]

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – April 7, 2023 Read More »

Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)

Merck, known as MSD outside of the United States and Canada, and Eisai provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai.

Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017) Read More »

AnPac Bio-Medical Science Announces Closing of $3.0 Million Registered Direct Offering

AnPac Bio-Medical Science Co., Ltd. announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares, pre-funded warrants to purchase ADSs and warrants to purchase ADSs.

AnPac Bio-Medical Science Announces Closing of $3.0 Million Registered Direct Offering Read More »

Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase III Trial for Chronic Obstructive Pulmonary Disease (“COPD”)

Nuance Pharma announces dosing of first patient in the ENHANCE – China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease of its novel solution Ensifentrine in mainland China.

Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase III Trial for Chronic Obstructive Pulmonary Disease (“COPD”) Read More »

Scroll to Top